Sudarshan Pharma warrants meet set for June 11
Sudarshan Pharma Industries Ltd has scheduled a Warrants Committee meeting for June 11, 2026, to approve the conversion of warrants and the allotment of equity shares. The meeting follows Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Joint Managing Director Sachin Mehta confirmed the agenda focuses on capital structure adjustments.
*this image is generated using AI for illustrative purposes only.
Sudarshan Pharma Industries Ltd has scheduled a meeting of its Warrants Committee for June 11, 2026, to consider the conversion of warrants into equity shares. The committee will review and approve the conversion of warrants and the allotment of the resulting equity shares to eligible applicants. This move is aimed at adjusting the company's capital structure in accordance with the terms of the warrant issuance.
The meeting is being convened pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates that companies obtain necessary approvals for alterations in their capital structure, including the conversion of securities such as warrants into equity shares. The committee's decision will finalize the number of shares to be allotted following the conversion process.
Sachin Mehta, Joint Managing Director of Sudarshan Pharma Industries Ltd, communicated the schedule to the stock exchanges. The filing confirmed that the primary agenda for the meeting is the approval of the conversion mechanism and the allotment of equity shares arising from the exercise of warrants. The company has requested the exchanges to place this information on record.
Key Meeting Details
| Detail | Information |
|---|---|
| Event | Warrants Committee Meeting |
| Date | June 11, 2026 |
| Purpose | Conversion of warrants and allotment of equity shares |
| Regulatory Reference | Regulation 29 of SEBI (LODR) Regulations, 2015 |
The approval from the Warrants Committee is a procedural step required before the equity shares can be officially credited to the accounts of the warrant holders. Once allotted, these shares will increase the company's outstanding equity capital.
Historical Stock Returns for Sudarshan Pharma Industries
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.74% | +1.89% | +15.51% | +45.11% | +7.73% | +404.32% |
How will the conversion of warrants into equity shares impact Sudarshan Pharma's earnings per share (EPS) in the upcoming fiscal year?
What are the potential market reactions to the dilution of existing shareholders' equity once the new shares are allotted?
Will the increased equity capital from warrant conversion be utilized for funding new projects or reducing existing debt?
16
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
